Viking Therapeutics’ Obesity Drug Shows Promising Clinical Outcomes

Viking Therapeutics is generating significant attention in the biotech sector with new clinical findings for its experimental weight-loss treatment, VK2735. The company is showcasing these results at two major medical conferences this week, potentially strengthening its competitive stance in the lucrative obesity medication market against established players like Eli Lilly and Novo Nordisk.

The data presentations coincide with the conclusion of ObesityWeek® 2025 in Atlanta and the commencement of the American Heart Association (AHA) 2025 Scientific Sessions in New Orleans, which runs through November 10.

Impressive Metabolic Improvements Revealed

During yesterday’s ObesityWeek® conference, Viking disclosed fresh clinical data through a poster presentation. The findings stem from an exploratory analysis of its Phase 2 VENTURE trial, a 13-week study investigating VK2735—a dual agonist targeting both GLP-1 and GIP receptors, employing a mechanism similar to other highly successful weight management drugs.

Key outcomes from the research demonstrate substantial enhancements in cardiometabolic health:

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

• Normal blood glucose levels were achieved by 78% of prediabetic patients, compared to just 29% in the placebo group
• A diagnosis of metabolic syndrome no longer applied to 68% of affected patients following treatment, versus 38% receiving placebo
• Participants experienced mean weight reduction reaching 14.7% over 13 weeks, with the treatment demonstrating a favorable safety profile

Phase 3 Trial Design and Cardiovascular Focus at AHA

Attention now shifts to the AHA Scientific Sessions, where Viking has scheduled two additional presentations. One will outline the design of the ongoing Phase 3 VANQUISH-2 study, which assesses the subcutaneous formulation of VK2735 in patients with obesity or overweight who also have Type 2 diabetes. A separate presentation will detail analytical results concerning the prevalence of cardiometabolic diseases across various BMI categories.

These developments are particularly crucial for Viking Therapeutics, a clinical-stage company without any commercialized products. The robust data not only validate its scientific approach but have also sparked market speculation about potential acquisition interest from larger pharmaceutical corporations. The company maintains a solid financial position to support its Phase 3 programs, reporting cash reserves of $715 million as of the third quarter’s conclusion in 2025.

Market experts and investors are closely monitoring patient recruitment progress for the VANQUISH Phase 3 trials, with results anticipated in 2027 and 2028.